Search bioRxiv⌕ Search

Biology subjects

Arpicco, S.

Publications and source records attributed to Arpicco, S..

2 recordsLinked to original sources

Dissecting Annexin-A11 into its functional domains revealed calcium as a key regulator for RNA transport and its association with ALS

Recent studies reveal a "hitchhiking" mechanism in neurons, where organelles transported along microtubules carry other cargos via tethering molecules. Annexin A11 (ANXA11), a calcium-dependent phospholipid-binding protein, functions as a tether linking RNA granules to lysosomes, aiding mRNA transport for rapid neuronal responses. Structurally, its N-terminal (Nt) binds RNA, while the C-terminal (Ct) associates with lysosomal membranes. Mutations in ANXA11 linked to Amyotrophic lateral sclerosis (ALS) may disrupt this function. Here, applying a multidisciplinary approach, we revealed that Ca2+ acts as a master regulator of ANXAlls physiological function by modulating its conformational states. Specifically, Ca2+ influences a switch between two conformations: a close state, in which the Nt and Ct interact with each other, and an open state, which occurs in the presence of Ca2+ ions, where this self-interaction is disrupted, allowing the two domains to interact freely with RNA and liposomes. Surprisingly, we observed that both the Ct and Nt are capable of interacting with liposomes and RNA in a Ca2+-dependent manner, and these interactions can occur simultaneously. This dual binding and its calcium-regulated hierarchy finely tunes ANXAlls binding to RNA and lysosomes, promoting a large complex essential for overcoming transport steric hindrance. Moreover, our result showed that the p.D40G mutation, in the Nt domain, associated with ALS, displays destabilized interdomain interactions and bypass Ca2+ regulation, leading to aberrant aggregation. These insights advance our understanding of ANXAlls role in neuronal RNA transport and its disruption in neurodegeneration, highlighting potential targets for therapeutic intervention.

biochemistry↗

Polymeric nanoparticles delivery of AMPK activator 991 prevents its toxicity and improves muscle homeostasis in Duchenne Muscular Dystrophy

Muscular dystrophies, such as Duchenne muscular dystrophy (DMD), are caused by permanent muscle injuries leading to chronic inflammation. In that context, macrophages harbor an altered inflammatory profile that contributes to fibrosis through the secretion of the profibrotic cytokine TGF{beta}1. We previously showed that AMP-activated protein kinase (AMPK) activation reduces TGF{beta}1 secretion by macrophages and improves muscle homeostasis and muscle force in a mouse model of DMD. This makes AMPK an attractive therapeutic target for treating chronic inflammation and fibrosis in DMD. However, potent direct AMPK activators like compound 991 show strong adverse effects in vivo, preventing their direct use. Here, we encapsulated 991 into biodegradable polymeric poly(lactic-co-glycolic) acid (PLGA) nanoparticles for in vivo delivery, in an attempt to overcome toxicity issues. We show that 991-loaded PLGA nanoparticles retained drug activity on fibrotic macrophages in vitro, by reducing their secretion of TGF{beta}1. In the D2-mdx pre-clinical DMD mouse model, intravenously injected PLGA nanoparticles reached gastrocnemius and diaphragm muscles, which are the most affected muscles in this model. Chronic intravenous injections of 991-loaded PLGA nanoparticles decreased inflammation in both muscles, which was associated with fibrosis reduction and increase in myofiber size and muscle mass in the gastrocnemius. No impact on blood cell counts and liver enzymes was observed. These results demonstrate that nanomedicine is an efficient strategy to deliver AMPK activators in vivo to target inflammation and improve the dystrophic muscle phenotype.

pathology↗